Citadel Advisors
LPCN icon

Citadel Advisors’s Lipocine LPCN Stock Holding History

Citadel Advisors’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,753
Closed -$9.48K – 14857
2023
Q1 		$9.48K Sell
1,753
-3,606
-67% -$27.9K ﹤0.01% 13584
2022
Q4 		$35K Buy
5,359
+1,077
+25% +$7.85K ﹤0.01% 12571
2022
Q3 		$33K Sell
4,282
-842
-16% -$9.4K ﹤0.01% 11847
2022
Q2 		$70K Buy
5,124
+465
+10% +$7.25K ﹤0.01% 11707
2022
Q1 		$109K Sell
4,659
-4,929
-51% -$103K ﹤0.01% 12197
2021
Q4 		$162K Sell
9,588
-3,241
-25% -$60.2K ﹤0.01% 12167
2021
Q3 		$238K Buy
12,829
+976
+8% +$21.5K ﹤0.01% 11586
2021
Q2 		$282K Buy
11,853
+2,729
+30% +$64.2K ﹤0.01% 11414
2021
Q1 		$234K Buy
9,124
+5,112
+127% +$148K ﹤0.01% 11395
2020
Q4 		$93K Buy
4,012
+794
+25% +$19.1K ﹤0.01% 10267
2020
Q3 		$77K Buy
3,218
+2,200
+216% +$58.4K ﹤0.01% 9415
2020
Q2 		$22K Buy
1,018
+212
+26% +$2.75K ﹤0.01% 9533
2020
Q1 		$7K Buy
+806
New +$6.38K ﹤0.01% 9457
2019
Q2 		– Sell
-1,124
Closed -$44K – 9557
2019
Q1 		$44K Sell
1,124
-158
-12% -$4.85K ﹤0.01% 8872
2018
Q4 		$28K Sell
1,282
-2,218
-63% -$51.4K ﹤0.01% 8640
2018
Q3 		$82K Buy
+3,500
New +$86.1K ﹤0.01% 8650
2018
Q1 		– Sell
-2,200
Closed -$129K – 8559
2017
Q4 		$129K Buy
2,200
+329
+18% +$20.5K ﹤0.01% 7334
2017
Q3 		$126K Buy
1,871
+889
+91% +$64.3K ﹤0.01% 6951
2017
Q2 		$67K Buy
+982
New +$64.1K ﹤0.01% 7020

Other funds holding LPCN

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Citadel Advisors's LPCN Position: Q1 2026 in Review

Citadel Advisors opened a new position in Lipocine (LPCN) in Q1 2026: 29,088 shares worth $232K. The stake represents ﹤0.01% of the portfolio and ranks #11090 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in LPCN as recently as Q3 2025.

Citadel Advisors first reported a position in LPCN in Q3 2015 and has held it in 16 quarters since. The position peaked at $820K in Q3 2015. 47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.

  • Citadel Advisors held 29,088 shares of Lipocine worth $232K as of Q1 2026.
  • Lipocine was a new Citadel Advisors position in Q1 2026.
  • Lipocine made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11090 holding.
  • Citadel Advisors first reported a position in Lipocine in Q3 2015 and has held it in 16 quarters since.
  • Citadel Advisors's Lipocine position peaked at $820K in Q3 2015.
  • 47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.